Biocon Limited
Bajaj Allianz Life Insurance bought 626,000 shares of Biocon for ₹25.04 crore at ₹400.00 apiece in a block deal. On the same day, Mylan (a part of Viatris) exited Biocon by selling its entire 5.64% stake, around 9.2 crore shares, for approximately ₹3,680 crore at an average price of ₹400 per share.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Now wholly owned by Bajaj Finserv after the Bajaj Group bought out Allianz SE's 26% stake in March 2025 for Rs 24,180 crore. Total AUM over Rs 1.2 lakh crore. Flagship Pure Stock Fund manages over Rs 7,200 crore as a Shariah-compliant Indian equity book. Active investor across large and midcap names through ULIP and group fund vehicles.